全文获取类型
收费全文 | 168篇 |
免费 | 9篇 |
专业分类
儿科学 | 2篇 |
妇产科学 | 2篇 |
基础医学 | 10篇 |
口腔科学 | 22篇 |
临床医学 | 4篇 |
内科学 | 13篇 |
神经病学 | 1篇 |
特种医学 | 1篇 |
外科学 | 13篇 |
预防医学 | 1篇 |
眼科学 | 1篇 |
药学 | 45篇 |
肿瘤学 | 62篇 |
出版年
2023年 | 1篇 |
2022年 | 2篇 |
2021年 | 4篇 |
2020年 | 6篇 |
2019年 | 5篇 |
2018年 | 18篇 |
2017年 | 9篇 |
2016年 | 10篇 |
2015年 | 16篇 |
2014年 | 21篇 |
2013年 | 16篇 |
2012年 | 8篇 |
2011年 | 16篇 |
2010年 | 3篇 |
2008年 | 5篇 |
2007年 | 6篇 |
2006年 | 6篇 |
2005年 | 7篇 |
2004年 | 2篇 |
2003年 | 1篇 |
2002年 | 3篇 |
2001年 | 1篇 |
2000年 | 2篇 |
1999年 | 1篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1979年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有177条查询结果,搜索用时 921 毫秒
1.
A Berruti M Tucci D Generali A Mosca M Ardine F Vana L Dogliotti 《Annals of oncology》2006,17(12):1854-1855
In their recent review article, Tanvetyanon and Stiff [1] pointedout that hypocalcemia is a frequent side-effect of intravenousbisphosphonates. This adverse event is usually mild and exceptionallysymptomatic, with the principle risk factors being pre-existinghypovitaminosis D, previous parathyroid surgery and intestinalresections. A direct consequence of hypocalcemia 相似文献
2.
3.
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to ude.uk@larenegj. 相似文献
4.
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to ude.uk@larenegj. 相似文献
5.
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to ude.uk@larenegj. 相似文献
6.
Bertoldi Carlo Monari Emanuela Cortellini Pierpaolo Generali Luigi Lucchi Andrea Spinato Sergio Zaffe Davide 《Clinical oral investigations》2020,24(2):1001-1011
Clinical Oral Investigations - To compare the clinical and histological response of supracrestal periodontal tissues to subgingival composite restorations versus natural root surfaces In 29... 相似文献
7.
Background:
National safety guidelines were developed to minimize the occurrence of serious adverse drug events (ADEs) associated with the use of the fentanyl transdermal system (FTS), however, reports of use in opioid-naïve patients for treatment of acute pain and associated ADEs continue to occur.Objective:
To evaluate the prescribing patterns of the FTS for adherence to recent US regulatory recommendations and identify the impact of health information technology (HIT) on adherence rates.Methods:
A retrospective pre- and postintervention analysis was performed in hospitalized adult patients receiving FTS. Electronic medication order instructions and text questions were incorporated into FTS electronic medication orders. The primary outcome measure was adherence of FTS medication orders to regulatory guidelines defined as (a) a new order in an opioid-tolerant patient for use in moderate to severe chronic pain or (b) continuation of the documented home dose in use for at least 7 days. Safety measures included respiratory rate and documented ADEs.Results:
Adherence rates were significantly increased in the postintervention cohort as compared to the preintervention cohort (48.7% vs 85.0%; P < .0001). Incidence of ADEs was significantly lower post intervention (34.7% vs 23.3%; P = .043), including a lower incidence of respiratory depression (16.7% vs 8.3%; P = .043). Documentation was increased in the postintervention cohort (76% vs 100%). However, supporting documentation confirmed responses in only 59.2% of records reviewed.Conclusions:
Incorporation of HIT via electronic order text questions increased overall adherence rates to regulatory recommendations, increased documentation, and decreased the rate of associated ADEs. 相似文献8.
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to ude.uk@larenegj. 相似文献
9.
This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to ude.uk@larenegj. 相似文献
10.
Chiara Masetti Elena Generali Francesca Colapietro Antonio Voza Maurizio Cecconi Antonio Messina Paolo Omodei Claudio Angelini Michele Ciccarelli Salvatore Badalamenti G. Walter Canonica Ana Lleo Alessio Aghemo the for the Humanitas Covid- Task Force 《European journal of clinical investigation》2020,50(9):e13314